By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



The Magdalen Centre
Robert Robinson Avenue
Oxford Science Park  Oxford   OX4 4GA   United Kingdom
Phone: 44-0-1865-784250 Fax: 44-0-1865-784251



Company News
Circassia (CIR.L) Release: Completion Of Acquisition Of Prosonix 6/15/2015 10:18:50 AM
Circassia (CIR.L) Drops $377 Million for Two Asthma Firms, Aerocrine and Prosonix 5/15/2015 6:02:17 AM
Prosonix Confirms The Potential Of Its Multi-Component Particleâ„¢ Technology For Developing Novel Inhaled Dual And Triple Combination Therapies For Respiratory Diseases 9/11/2014 9:29:13 AM
Prosonix' Marketing Authorisation Application For PSX1001 - A Generic Version Of GlaxoSmithKline (GSK)'s Flixotide® Evohaler® - Under Assessment In EU 9/2/2014 1:06:11 PM
Prosonix To Present Results Of Phase 2 Clinical Study Of PSX1002 In Chronic Obstructive Pulmonary Disease (COPD) At The American Thoracic Society Meeting 5/15/2014 7:32:12 AM
Prosonix Reports Positive Top-Line Results From Its Phase 2 Clinical Study With PSX1002 In Moderate To Severe Chronic Obstructive Pulmonary Disease (COPD) 1/23/2014 8:24:15 AM
Final Patient Completes Prosonix' Phase 2 Clinical Study with PSX1002 in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) 8/16/2013 10:18:18 AM
Prosonix Appoints Frank Condella as Non-executive Director 7/1/2013 6:32:40 AM
Prosonix Initiates Phase 2 Clinical Study With PSX1002 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) 5/22/2013 9:49:06 AM
Prosonix Sets Date for First Quarter Fiscal Year 2013 Earnings Release: August 2, 2012 7/5/2012 10:49:55 AM